Status:

COMPLETED

Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module

Lead Sponsor:

Heidelberg Engineering GmbH

Conditions:

Retinal Vascular

Normal Eyes

Eligibility:

All Genders

22+ years

Brief Summary

Assessment of image quality and clinical relevance of OCT Angiography via comparison to FA/ICGA.

Detailed Description

The objectives of this study are: 1. To compare the OCTA image quality between the SPECTRALIS and the predicate. 2. To compare the agreement of clinical findings on SPECTRALIS OCTA to the predicate.

Eligibility Criteria

Inclusion

  • All subjects:
  • Able and willing to undergo the test procedures, sign informed consent, and follow instructions.
  • Age ≥ 22
  • Subjects with Normal Eyes:
  • Subjects presenting at the site without uncontrolled systemic conditions, or ocular disease, as determined by the Investigator
  • Corrected visual acuity ≥ 20/40 in each eye
  • No history of ocular surgical intervention (except for refractive or cataract surgery) in either eye
  • Subjects with Pathology:
  • Subjects with retinal conditions in at least one eye.
  • Subjects included can have a range of retinal vascular pathologies affecting different anatomic depths through the retina and choroid. Retinal conditions including but not limited to diabetic retinopathy, wet age-related macular degeneration (AMD), and branch or central retinal vein occlusion that give rise to features such as retinal ischemia, microaneurysms, choroidal neovascularization and retinal neovascularization will be included.

Exclusion

  • Subjects unable to read or write
  • Subjects with ocular media not sufficiently clear to obtain acceptable study-related imaging
  • Subjects who cannot tolerate the imaging procedures
  • Subjects with known allergies to fluorescein dye, Indocyanine Green (ICG), shellfish, drugs for pupillary dilation
  • Subjects with contraindication to pupillary dilation in study eye

Key Trial Info

Start Date :

August 23 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 12 2018

Estimated Enrollment :

88 Patients enrolled

Trial Details

Trial ID

NCT03279939

Start Date

August 23 2017

End Date

January 12 2018

Last Update

September 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Retina Consultants of Houston

Houston, Texas, United States, 77030

Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module | DecenTrialz